Byondis B.V.

Quick facts

Phase 3 pipeline

• (vic-)trastuzumab duocarmazine · Oncology
  Trastuzumab duocarmazine is an antibody-drug conjugate that binds HER2-positive cancer cells and delivers a DNA-damaging payload intracellularly.

Phase 2 pipeline

• SYD985

Phase 1 pipeline

• BYON3521
• BYON4413
• BYON5667 & SYD985
• SYD1875

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Byondis B.V. portfolio CI brief
• Byondis B.V. pipeline updates RSS